RxSight (NASDAQ: RXST) has recently received a number of price target changes and ratings updates:
- 11/12/2026 – RxSight was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
- 11/7/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
- 11/4/2026 – RxSight had its price target lowered by Wells Fargo & Company from $9.00 to $6.00. They now have an “equal weight” rating on the stock.
- 11/4/2026 – RxSight had its price target lowered by Piper Sandler from $10.00 to $8.00. They now have a “neutral” rating on the stock.
- 11/4/2026 – RxSight had its price target lowered by Needham & Company LLC from $11.00 to $7.00. They now have a “buy” rating on the stock.
- 10/25/2026 – RxSight was downgraded by Wall Street Zen from “hold” to “sell”.
- 10/17/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
- 10/3/2026 – RxSight was downgraded by Wall Street Zen from “hold” to “sell”.
- 9/22/2026 – RxSight had its price target lowered by Jefferies Financial Group from $6.50 to $5.75. They now have a “hold” rating on the stock.
- 9/22/2026 – RxSight had its price target lowered by Bank of America from $6.50 to $5.50. They now have an “underperform” rating on the stock.
- 9/20/2026 – RxSight was upgraded by Wall Street Zen from “sell” to “hold”.
RxSight Stock Up 3.7%
Shares of RxSight stock opened at $5.01 on Thursday. The stock has a market capitalization of $210.07 million, a price-to-earnings ratio of -3.91 and a beta of 1.21. RxSight, Inc. has a twelve month low of $4.11 and a twelve month high of $13.22. The company has a 50-day simple moving average of $4.96 and a two-hundred day simple moving average of $6.09.
RxSight (NASDAQ:RXST – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08). RxSight had a negative return on equity of 20.11% and a negative net margin of 43.80%. The business had revenue of $24.59 million for the quarter, compared to analyst estimates of $27.19 million. On average, sell-side analysts anticipate that RxSight, Inc. will post -0.78 earnings per share for the current fiscal year.
Insider Activity at RxSight
RxSight, Inc. is a medical technology company focused on products for cataract surgery and vision correction. Its main offering is the Light Adjustable Lens (LAL), an intraocular lens implanted during cataract surgery that can be adjusted after the procedure to refine a patient’s vision. Adjustments are made with RxSight’s Light Delivery Device, which uses ultraviolet light to change the lens’s optical power. The company also provides related treatment-planning and patient-care products and services for clinicians using the LAL system.
Read More
- Five stocks we like better than RxSight
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for RxSight Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight Inc and related companies with MarketBeat.com's FREE daily email newsletter.
